Recombinant Zoster Vaccine Safety and Immunogenicity in SD Rats

21.4 KB of tabular data from a non-clinical safety assessment of a recombinant zoster vaccine (CHO cell) formulated with adjuvant BC02. The dataset, authored by Qian Yang and published on figshare in 2026, likely contains results from repeated dose toxicity and immunogenicity studies in Sprague-Dawley rats.

Use Cases

• Assessing vaccine safety based on general health observations and histopathological evaluations mentioned in the description
• Evaluating immunotoxicity based on immunotoxicity assays mentioned in the description
• Analyzing immunogenicity based on cellular and humoral response assays mentioned in the description
• Determining a no-observed-adverse-effect level (NOAEL) based on the reported 1.0 mL per rat dose

Strengths

• The dataset reports a specific NOAEL of 1.0 mL per rat, equivalent to two human doses
• The description indicates a systematic toxicology program covering multiple assessment methods

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment

Provenance

Source

Qian Yang

Collection Method

Non-clinical safety assessment involving general health observations, immunotoxicity and immunogenicity assays, hematological and biochemical profiling, and histopathological evaluations.

Freshness

Last updated 2026-05-22 05:35:49